NetworkNewsWire
Editorial Coverage: A tsunami has started: Cannabidiol (CBD), a
non-psychoactive compound found in the cannabis sativa plant, has
shown tremendous promise for broad-ranging medical benefits, and
consumers are taking notice. CBD products are derived from either
industrial hemp or marijuana plants, and sales have soared as
companies scramble to exploit the enormous opportunity. Total CBD
sales exceeded $200 million in 2016, and conservative projections
peg overall sales in excess of $2.1 billion by 2020, a
700% increase from 2016. The hemp-derived CBD
market is projected to grow at an astounding compounded annual
growth rate approaching 55% over the next five years, positioning
it as the fastest growing sub-segment within the
multi-billion-dollar legal cannabis and hemp market. Some of the
most promising players in the space include PotNetwork
Holding Inc. (POTN) (POTN
Profile), given a four-fold price target by a an
equity research firm, Terra Tech Corp (TRTC),
INSYS Therapeutics Inc. (INSY), Cannabis
Science Inc. (CBIS) and 22nd Century Group Inc.
(XXII).
Thousands of scientific studies tout the benefits of medical
CBD. Research continues to be encouraging for CBD’s anti-seizure
properties, singularly effective in treating certain epilepsies.
Its effect on epilepsy and lack of significant side effects makes
CBDs an attractive treatment option for multiple neurological
disorders such as neurodegeneration, neuronal injury, and
psychiatric diseases. CBD significantly reduces inflammation, and
is already used to treat chronic pain, multiple sclerosis, and
fibromyalgia. CBD has also demonstrated promising therapeutic
results treating multiple anxiety disorders, mood symptoms,
rheumatoid arthritis, nausea and insomnia. But the list of benefits
is only growing. It appears to ease inflammation in the pancreas in
Type 1 diabetes; there’s evidence that it has potential to prevent
Alzheimer's disease symptoms; and CBD appears to suppress the
growth of cancer cells and promote the death of these cells
(http://nnw.fm/Gag71). In multiple studies, CBD
has been well-tolerated in adults across a wide range of dosages.
With so many direct applications, the prospects of combination
pharmaceutical therapies and the promise of a myriad of new
remedies, it is little wonder the CBD market is exploding, and
companies are vying to capitalize on the immense opportunity.
Through its subsidiaries, PotNetwork
Holding (POTN) researches, develops and sells premium
hemp extracts throughout the U.S. and internationally. The
company’s products are made with federally legal hemp-derived CBD,
and are available in a variety of flavors and sizes tailored to
exceed consumer needs and expectations. As the primary operating
entity of PotNetwork, Diamond CBD, Inc. produces and markets 15
different CBD brands that have gained international acceptance for
both quality and consistency. With its staff of scientists and
chemists, Diamond CBD develops and produces only the highest
quality CBD oil across multiple product lines for specific
medicinal uses. Scientific research and depth of knowledge of
natural hemp molecules and their properties determine the course of
new product development. The company insists on 100% natural
lab-tested CBD ingredients, with the process meticulously monitored
from the source farm through every stage of production and final
delivery to retail outlets.
To deliver and expand products of exceptional quality and
efficacy, PotNetwork is building a team of medical professionals
with knowledge and expertise in the intricacies of CBD and how to
best achieve optimal therapeutic results. Keeping with strategy,
PotNetwork recently appointed Dr. Richard Goulding, MD as its chief
executive officer (http://nnw.fm/6HEfH). A veteran of medical science
with extensive knowledge of CBD’s prophylactic benefits, Dr.
Goulding will be instrumental in directing the company’s mission to
develop scientifically targeted formulas designed to deliver
consistent results for a wide spectrum of maladies. His insight on
the latest research utilizing cannabis for multiple medical
applications is expected to strongly enhance the company’s ability
to excel in the marketplace. As Dr. Goulding stated in a press
release announcing his appointment, “From what I’ve been able to
discover, it seems we have only scratched the surface in this
marketplace. It truly is an optimum time to be involved in an
industry whose time has come.”
Not alone in his assessment, equity research firm SeeThruEquity
identifies a “burgeoning legal cannabis and hemp industry,” and
said it expects PotNetwork to increase YOY revenues 712% in fiscal
year 2017, driven by new product launches, aggressive marketing
initiatives, and entry into new markets (http://nnw.fm/xZ4jH). The report sets a price target
of $0.25 per share for POTN, four times the current level.
PotNetwork has 484 million shares outstanding and a market
capitalization of $29 million.
As a cannabis-focused agriculture company, Terra Tech
Corp. (TRTC) produces, extracts and distributes medical
cannabis, and is engaged in plant science research and development,
food production, and closed environment agriculture. The company
operates through multiple subsidiary businesses, including: Blüm,
its retail and medical cannabis facilities; IVXX Inc., which
produces cannabis extracted products for medical cannabis
dispensaries in California and Nevada; Edible Garden, which
cultivates and sells local and sustainably grown hydroponic
produce; and MediFarm LLC, which is focused on medical and
adult-use cannabis cultivation and permitting businesses in Nevada.
The company has nearly 665 million shares outstanding and carries a
hefty $135+ million market capitalization.
INSYS Therapeutics Inc. (INSY) develops and
commercializes innovative drugs and drug delivery systems. INSYS
currently markets two products: Subsys®, which is sublingual
Fentanyl spray for breakthrough cancer pain; and a generic version
of Dronabinol, a synthetic chemical form of tetrahydrocannabinol
(THC). In 2011, the company launched its Dronabinol SG Capsule, a
generic equivalent to Marinol (synthetic THC), an approved
second-line treatment for chemotherapy-induced nausea and vomiting
and anorexia associated with weight loss in AIDS patients. In 2012,
the company launched its proprietary sublingual fentanyl spray for
breakthrough cancer pain. Since late 2014, Subsys® has been the
most prescribed transmucosal immediate-release fentanyl product
with 48% market share on a prescription basis. This enormous market
share is in part explanatory of the company’s eye-popping 203 PE
ratio and a market cap of $664 million. There are almost 73 million
shares outstanding and big money is well positioned with 28%
institutional ownership.
Engaged in medical marijuana research and development,
Cannabis Science Inc. (CBIS) works on
phytocannabinoids to target critical illnesses and adheres to
scientific methodologies to develop, produce, and commercialize
phytocannabinoid-based pharmaceutical products. The company is
involved in the creation of cannabis-based medicines, with and
without psychoactive properties, to treat disease and the symptoms
of disease. Cannabis Science’s products are medical cannabinoid
formulations developed from one or more of the cannabinoid
compounds found in the cannabis plant and the company focuses on
development of governmentally approved pharmaceuticals. The company
has 2.5 billion shares outstanding and market cap of $87
million.
Through genetic engineering and plant breeding, 22nd
Century Group Inc. (XXII) can increase or decrease the
level of nicotine and nicotinic alkaloids in tobacco plants and the
levels of cannabinoids in cannabis plants. The company’s primary
mission in tobacco is to reduce the harm caused by smoking and its
primary mission in cannabis is to develop proprietary hemp/cannabis
strains for new medicines and agricultural crops. The company is
engaged in research and development of specialized plant varieties
of hemp/cannabis, such as plants with low to no amounts of THC;
plants with high levels of CBD and other non-THC cannabinoids;
research and development of less harmful tobacco products and
tobacco plant varieties; and a smoking cessation aid consisting of
very low nicotine cigarettes. Not a pure CBD play, the company has
102 million shares outstanding and a market cap of $293
million.
According to research from Brightfield Group and HelloMD, 80
percent of all people who use CBD found the products to be “very or
extremely effective,” and nearly half of all CBD users actually
stop taking traditional medications like Tylenol or prescription
drugs like Vicodin, as reported by Forbes (http://nnw.fm/30jLR). With such overwhelming
endorsement by retail consumers of medicinal cannabidiol, there is
little doubt that CBD is becoming a mainstream therapeutic that
will continue to grow in market size and acceptance.
For more information on PotNetwork Holding
Inc., visit PotNetwork
Holding (POTN)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com